Some recent analyst ratings include

• 10/22/2019-
  Aclaris Therapeutics Inc (NASDAQ:ACRS) gets upgraded to Outperform by Leerink Swann
• 10/22/2019-
  Aclaris Therapeutics Inc (NASDAQ:ACRS) gets upgraded to Outperform by Svb Leerink
• 10/11/2019-
  Aclaris Therapeutics Inc (NASDAQ:ACRS) had its Buy rating reiterated by William Blair
• 9/6/2019-
  Aclaris Therapeutics Inc (NASDAQ:ACRS) gets downgraded to Market Perform by JMP Securities
• 8/9/2019-
  Aclaris Therapeutics Inc (NASDAQ:ACRS) had its Overweight rating reiterated by Cantor Fitzgerald with a $5.00 price target
• 2/8/2018-
  Aclaris Therapeutics Inc (NASDAQ:ACRS) has coverage initiated with a Buy ➝ Buy rating and $53.00 price target

• On 6/27/2019 James E Flynn, Major Shareholder, sold 699,475 with an average share price of $2.69 per share and the total transaction amounting to $1,881,587.75.
• On 6/25/2019 James E Flynn, Major Shareholder, sold 454,261 with an average share price of $4.59 per share and the total transaction amounting to $2,085,057.99.
• On 6/21/2019 James E Flynn, Major Shareholder, sold 339,537 with an average share price of $4.62 per share and the total transaction amounting to $1,568,660.94.
• On 5/10/2019 James E Flynn, Major Shareholder, sold 614,710 with an average share price of $6.13 per share and the total transaction amounting to $3,768,172.30.
• On 10/22/2018 Anand Mehra, Director, bought 372,093 with an average share price of $10.75 per share and the total transaction amounting to $3,999,999.75.
• On 10/4/2018 Stephen A Tullman, Director, bought 7,100 with an average share price of $14.00 per share and the total transaction amounting to $99,400.00.
• On 8/23/2018 Stephen A Tullman, Director, bought 6,600 with an average share price of $15.00 per share and the total transaction amounting to $99,000.00.

Recent Trading Activity for